Log in to save to my catalogue

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Ena...

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Ena...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3070784725

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform

About this item

Full title

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform

Publisher

Washington: American Chemical Society

Journal title

ChemRxiv, 2024-06

Language

English

Formats

Publication information

Publisher

Washington: American Chemical Society

More information

Scope and Contents

Contents

Despite the success of first, second and third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in treatment of non-small cell lung cancer (NSCLC) with classical EGFR mutations (L858R or Exon 19 deletions), disease progression often occurs due to the acquisition of additional mutations in the EGFR kinase domain t...

Alternative Titles

Full title

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_3070784725

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3070784725

Other Identifiers

E-ISSN

2573-2293

DOI

10.26434/chemrxiv-2024-5rzt9-v2

How to access this item